| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5271 | 2021 |
| SARS-CoV-2 variants, spike mutations and immune escape WT Harvey, AM Carabelli, B Jackson, RK Gupta, EC Thomson, ... Nature Reviews Microbiology 19 (7), 409-424, 2021 | 3073 | 2021 |
| COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options TJ Guzik, SA Mohiddin, A Dimarco, V Patel, K Savvatis, FM Marelli-Berg, ... Cardiovascular research 116 (10), 1666-1687, 2020 | 1616 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1327 | 2021 |
| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1061 | 2021 |
| Safety and efficacy of NVX-CoV2373 Covid-19 vaccine PT Heath, EP Galiza, DN Baxter, M Boffito, D Browne, F Burns, ... New England Journal of Medicine 385 (13), 1172-1183, 2021 | 945 | 2021 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 901 | 2022 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 804 | 2022 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 737 | 2021 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 716 | 2021 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 660 | 2021 |
| Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 DA Collier, IATM Ferreira, P Kotagiri, RP Datir, EY Lim, E Touizer, B Meng, ... Nature 596 (7872), 417-422, 2021 | 615 | 2021 |
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity EC Thomson, LE Rosen, JG Shepherd, R Spreafico, A da Silva Filipe, ... Cell 184 (5), 1171-1187. e20, 2021 | 557 | 2021 |
| Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 424 | 2021 |
| SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway BJ Willett, J Grove, OA MacLean, C Wilkie, G De Lorenzo, W Furnon, ... Nature microbiology 7 (8), 1161-1179, 2022 | 414 | 2022 |
| Efficacy and safety of COVID-19 vaccines in older people RL Soiza, C Scicluna, EC Thomson Age and ageing 50 (2), 279-283, 2021 | 364 | 2021 |
| Late Ebola virus relapse causing meningoencephalitis: a case report M Jacobs, A Rodger, DJ Bell, S Bhagani, I Cropley, A Filipe, RJ Gifford, ... The Lancet 388 (10043), 498-503, 2016 | 364 | 2016 |
| Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 338 | 2021 |
| SARS-CoV-2 within-host diversity and transmission KA Lythgoe, M Hall, L Ferretti, M de Cesare, G MacIntyre-Cockett, ... Science 372 (6539), eabg0821, 2021 | 296 | 2021 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 278 | 2021 |
